FOLH1 and metastatic neoplasm: In a multivariate analysis of patients with BCR and no known metastasis (N = 1960), the BCR high-risk group had a higher likelihood of metastatic disease by PSMA PET compared with the low-risk group (odds ratio, 2.91; 95% CI 2.18–3.93) [62].